Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D014508:Urea / Q000627:therapeutic use*
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea